ONESOURCE SPECIALTY PHARMA
|
|
| BOM : 544292     NSE : ONESOURCE     | |
| LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Average [Stock is fairly valued] Debt : High |
Updated: |
| ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : Average [>25% and <50%] |
Aug 28,2026 |
|
Price(EOD): ₹ 1,533.00
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 17,583.51 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ONESOURCE SPECIALTY PHARMA | NA | -9% | -18.3% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.5% | -4% | 15.7% |
| DIVIS LABORATORIES | 9.1% | 18.2% | 47.1% |
| TORRENT PHARMACEUTICALS | 3.6% | 3.4% | 36.4% |
| CIPLA | -1.2% | -3.3% | -10.8% |
| DR REDDYS LABORATORIES | -1.4% | 2.9% | -8% |
| MANKIND PHARMA | 0.5% | -7.4% | -7.3% |
| LUPIN | -0.7% | -10.1% | 9.6% |
| ZYDUS LIFESCIENCES | 7.8% | 6.4% | 20.3% |
FUNDAMENTAL ANALYSIS OF ONESOURCE SPECIALTY PHARMA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF ONESOURCE SPECIALTY PHARMA
 | Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
-361.57
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs -48.62 Cr
[Latest Qtr - Jun2026 - Consolidated Results ] 3.01
P/B Calculated based on Book Value of Rs 5,831.29 Cr
[Latest Year - Mar2026 - Consolidated Results ] 11.39
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 1,543.34 Cr
[Latest Qtr - Jun2026 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
805% 3% -21% |
SHARE PRICE MOMENTUM OF ONESOURCE SPECIALTY PHARMA
ONESOURCE SPECIALTY PHARMA vs SENSEX
DEBT OF ONESOURCE SPECIALTY PHARMA
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2025 2024 2023 Avg_3yrs |
0.13 1.44 1.07 0.88 |
0.13 1.45 1.07 0.88 |
|
[Last Annual Data : Mar2025]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF ONESOURCE SPECIALTY PHARMA
| Pledged Promoter Shares |
37.23 % | |
|---|---|---|
| As on : Jun2026 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF ONESOURCE SPECIALTY PHARMA
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
4.86% 34.19% 7050% 443.77% |
37.2% 39.4% 561.33% 13539.2% |
| QtrlyTrend |
8 | |
| Latest Qtr: Jun2026 | ||
| Quarterly Result Analysis → | ||
ONESOURCE SPECIALTY PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE HEALTHCARE | 2.1% | 1.6% | 15.3% |
| BSE SELECT IPO INDEX | 0.6% | 4.7% | -1.7% |
| BSE 250 SMALLCAP INDEX | 0.5% | 2.7% | 6.5% |
| BSE 400 MIDSMALLCAP INDEX | 0.4% | 2.2% | 7.7% |
| BSE 1000 | -0% | 1% | 2% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MIDSMALL HEALTHCARE | 1.8% | 1.1% | 17.5% |
| NIFTY SMALLCAP 500 | 0.5% | 3.7% | NA |
| NIFTY SMALLCAP 250 | 0.4% | 2.9% | 8.3% |
| NIFTY MIDSMALLCAP400 50:50 | 0.4% | 2.3% | NA |
| NIFTY MIDSMALLCAP 400 | 0.4% | 2.1% | 9% |
You may also like the below Video Courses
FAQ about ONESOURCE SPECIALTY PHARMA
Is ONESOURCE SPECIALTY PHARMA good for long term investment?
As on Aug 28,2026, the Fundamentals of ONESOURCE SPECIALTY PHARMA look Poor and hence it may not be good for long term investment ! See Financial Performance of ONESOURCE SPECIALTY PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is ONESOURCE SPECIALTY PHARMA UnderValued or OverValued?
As on Aug 28,2026, ONESOURCE SPECIALTY PHARMA is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of ONESOURCE SPECIALTY PHARMA ?
As on Aug 28,2026, the Intrinsic Value of ONESOURCE SPECIALTY PHARMA is Rs. 1,491.70 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 169.46
Fair Value [Median EV / Sales Model] : Rs. 1,491.70
Fair Value [Median Price / Sales Model] : Rs. 1,942.15
Estimated Median Fair Value of ONESOURCE SPECIALTY PHARMA : Rs. 1,491.70
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.